Dehydration News and Research

Latest Dehydration News and Research

Diabetic individuals living in hot climate need increased 'heat awareness'

A new survey shows that diabetic individuals who live in a hot climate have important gaps in their "heat awareness," or knowledge about proper diabetes self-care in hot weather, even though diabetes raises their risk of heat illness. The results of "Diabetes in the Desert: What Do Patients Know About the Heat?" will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Diarrhea represents a major condition responsible for pediatric mortality worldwide. The onset of neonatal diarrhea may rapidly lead to life threatening dehydration and malnutrition. Clinical and epidemiologic studies defining severity and etiology are needed in order to improve diagnostic and therapeutic approaches for the management of neonatal diarrhea.

18 Jun 2010

WoundVision launches bedside thermographic imaging system

WoundVision™, the healthcare industry pioneer in advanced wound detection technology, is introducing today a revolutionary predictive bedside thermographic imaging system. The WoundVision system brings knowledge bedside by acquiring, analyzing and applying essential patient data to inform healthcare providers in the development of effective treatment and care plans.

14 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.

9 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma.

7 Jun 2010

June Cold Spring Harbor Protocols features electrophoresis in RNA analysis and avian embryos

Gel electrophoresis is one of the most important and frequently used techniques in RNA analysis. Electrophoresis is used for RNA detection, quantification, purification by size and quality assessment. Gels are involved in a wide variety of methods including northern blotting, primer extension, footprinting and analyzing processing reactions. The two most common types of gels are polyacrylamide and agarose.

5 Jun 2010

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Top physicians offer health advice to help people survive during summer

This summer a variety of top physicians at NewYork-Presbyterian Hospital are offering health advice to help survive the travails that come with one of the most active seasons of the year.

3 Jun 2010

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

A study published in the June issue of The Journal of Nuclear Medicine shows that positron emission tomography -a molecular imaging technique-combined with computer tomography colonography may provide a suitable alternative for detecting polyps and cancer in the colon. This particular imaging method may be especially desirable for patients because it does not require sedation or bowel preparation.

2 Jun 2010

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

Allos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be presented at two upcoming medical conferences: the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4-8 in Chicago, Illinois, and at the 15th Congress of the European Hematology Association (EHA), which will be held June 10-13 in Barcelona, Spain.

2 Jun 2010

New research shows microdebrider technique has lowest overall complication rate

In a review of three different surgical techniques commonly used for tonsillectomy, the microdebrider technique (where a rotary cutting tool is used to shave tissue) had the lowest overall complication rate when compared to the other two techniques. The results are shown in new research published in the June 2010 issue of Otolaryngology - Head and Neck Surgery.

1 Jun 2010

First Edition: May 27, 2010

Today's health policy headlines focus on a new study about the federal government's funding level for the high-risk pools set up in the new health law as well as congressional Democrats' ongoing struggle to pass legislation to extend the COBRA benefit subsidy and to prevent a scheduled cut in Medicare payments to physicians.

27 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Dehydration News and Research

Latest Dehydration News and Research

Diabetic individuals living in hot climate need increased 'heat awareness'

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

WoundVision launches bedside thermographic imaging system

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Caregiver's guide on avoiding life-threatening swallowing problems

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

June Cold Spring Harbor Protocols features electrophoresis in RNA analysis and avian embryos

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Top physicians offer health advice to help people survive during summer

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA Congress

New research shows microdebrider technique has lowest overall complication rate

First Edition: May 27, 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Dehydration News and Research

Latest Dehydration News and Research

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Newsletters you may be interested in